Status:
RECRUITING
Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
Lead Sponsor:
Epiliquid Holding, Inc
Conditions:
Colo-rectal Cancer
Eligibility:
All Genders
45-75 years
Brief Summary
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprie...
Detailed Description
This observational case-control study aims to evaluate the performance of delta-HLD technology in an average-risk colorectal cancer population. The CASCADE study seeks to validate the technical and di...
Eligibility Criteria
Inclusion
- Candidate for colonoscopy or colorectal surgery
- Willing and able to provide informed consent
- Able to provide blood and/or tissue sample before treatment or resection
Exclusion
- Prior history of colorectal cancer
- Inflammatory bowel disease
- Known hereditary cancer syndromes (e.g., Lynch, FAP)
- Other active malignancies
- Recent chemotherapy or immunosuppressive treatment
Key Trial Info
Start Date :
June 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT07148297
Start Date
June 30 2021
End Date
December 1 2026
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Epiliquid
Mendoza, Argentina, 5500